Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Investigational New Drugs"
DOI: 10.1007/s10637-019-00887-0
Abstract: Purpose The study evaluated the potential effect of dacomitinib, a small molecule epidermal growth factor receptor (EGFR) inhibitor, on the electrocardiogram (ECG) parameters in adult patients with advanced non-small cell lung cancer enrolled in a… read more here.
Keywords: ecg parameters; effect dacomitinib; dacomitinib; effect ... See more keywords
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of cancer"
DOI: 10.1016/j.ejca.2018.04.004
Abstract: BACKGROUND In recurrent or metastatic (R/M) skin squamous cell cancer (sSCC) not amenable to radiotherapy (RT) or surgery, chemotherapy (CT) has a palliative intent and limited clinical responses. The role of oral pan-HER inhibitor dacomitinib… read more here.
Keywords: skin squamous; squamous cell; skin; dacomitinib ... See more keywords
Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.12.008
Abstract: OBJECTIVE Dacomitinib is a potent, irreversible and pan-HER tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). Currently, evidence of its activity on brain metastasis is lacking. MATERIALS… read more here.
Keywords: egfr mutant; dacomitinib; metastasis; lung cancer ... See more keywords
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
Sign Up to like & getrecommendations! Published in 2021 at "Lung cancer"
DOI: 10.1016/j.lungcan.2021.02.025
Abstract: OBJECTIVES To compare efficacy and safety of dacomitinib versus gefitinib as first-line therapy for EGFR mutation-positive advanced NSCLC in Asian patients enrolled in the ongoing ARCHER 1050 trial. MATERIALS AND METHODS In this ongoing, randomized,… read more here.
Keywords: egfr mutation; first line; mutation positive; asian patients ... See more keywords
A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000030269
Abstract: Rationale: Uncommon epidermal growth factor receptor (EGFR) mutations are increasingly being identified in non-small cell lung cancer. Insertion and deletion mutations have been detected in exons 18, 19, and 20, but not in exon 21.… read more here.
Keywords: lung; patient; dacomitinib; indel mutation ... See more keywords
Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Science"
DOI: 10.1111/cas.14384
Abstract: In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we evaluated the efficacy and safety and determined the effects of dose modifications on adverse events (AE) and therapy management of… read more here.
Keywords: first line; safety; dacomitinib; japanese patients ... See more keywords
Dacomitinib Beats Gefitinib for EGFR+ NSCLC.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2017-089
Abstract: The irreversible EGFR inhibitor dacomitinib reduced the chance of lung cancer progression compared with an older, first-generation EGFR inhibitor, gefitinib, in a phase III trial. As reported at the 2017 American Society of Clinical Oncology… read more here.
Keywords: egfr; gefitinib egfr; egfr inhibitor; dacomitinib ... See more keywords
Real-world experience of dacomitinib in EGFR mutated advanced NSCLC: A single center experience from India.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e21043
Abstract: e21043 Background: Dacomitinib is an irreversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) approved in advanced non-small cell lung cancer (NSCLC) with mutated EGFR. Literature on real world experience of dacomitinib is lacking,… read more here.
Keywords: response; dacomitinib; oncology; egfr ... See more keywords
Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Management and Research"
DOI: 10.2147/cmar.s293983
Abstract: Background The objective of the study was to evaluate the economics of dacomitinib and gefitinib in the first-line treatments for EGFR-positive advanced or metastatic non-small cell lung cancer (NSCLC) from a US payer perspective. Methods… read more here.
Keywords: dacomitinib; cancer; first line; cost ... See more keywords
Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.
Sign Up to like & getrecommendations! Published in 2019 at "Future oncology"
DOI: 10.2217/fon-2018-0944
Abstract: Aim: This pooled safety analysis was conducted to analyze incidence and management of key dacomitinib-associated adverse drug reactions (ADRs). Patients & methods: Patients with EGFR mutation-positive advanced non-small-cell lung cancer who received first-line dacomitinib at… read more here.
Keywords: pooled safety; egfr mutation; mutation positive; dacomitinib ... See more keywords